Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Gunn | M | - |
Soricimed Biopharma, Inc.
 Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 19 years |
| Vaughn Embro-Pantalony | M | 66 |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 6 years |
| Tom Reeves | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
| Susan Hicks | F | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 6 years |
| Marc Rubin | M | 69 |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 6 years |
| Robert Bruce | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 5 years |
| Camille Belliveau | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kenneth N. Keirstead | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
| Rick Pryde | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 9 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jack Stewart
- Personal Network
